Skip to main
XTNT

XTNT Stock Forecast & Price Target

XTNT Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Xtant Medical Holdings is poised for success in the medical technology industry as it focuses on its core business of orthobiologics and spinal implants. With the recent Dilon Technologies agreement, a strong capital position, and a discounted valuation compared to its peers, Xtant Medical is positioned for revenue growth and profitability. The company's product pipeline, including the recent launch of Trivium Shaped, showcases its commitment to innovation and meeting the needs of orthopedic and neurological surgeons. Risks include competition, legacy performance, and the need for additional capital, but the company's recent changes and clean-up process demonstrate its ability to adapt and improve. Overall, Xtant Medical has a positive outlook for future growth and potential to provide value for investors.

Bears say

Xtant Medical Holdings is facing a potential growth plateau in the near-term due to their reliance on a single distributor for a significant portion of their revenue. Ongoing inventory dynamics in the wound care market may also hinder their ability to drive sales in this segment. Additionally, their limited financial resources may impede their ability to effectively compete with larger, more established competitors in the market.

XTNT has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Xtant Medical Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Xtant Medical Holdings (XTNT) Forecast

Analysts have given XTNT a Strong Buy based on their latest research and market trends.

According to 2 analysts, XTNT has a Strong Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Xtant Medical Holdings (XTNT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.